Interactome of the HIV-1 proteome and human host RNA
The human immunodeficiency virus (HIV-1) is highly dependent on a variety of host factors. Beside proteins, host RNA molecules are reported to aid HIV-1 replication and latency maintenance. Here, we implement multiple workflows of native RNA immunoprecipitation and sequencing (nRIPseq) to determine direct host RNA interaction partners of all 18 HIV-1 (poly)proteins. We identify 1,727 HIV-1 protein - human RNA interactions in the Jurkat cell line and 1,558 interactions in SupT1 cells for a subset of proteins, and discover distinct cellular pathways that seem to be used or controlled by HIV-1 on the RNA level: Tat binds mRNAs of proteins involved in the super elongation complex (AFF1-4, Cyclin-T1). Correlation of the interaction scores (based on binding abundancy) allows identifying the highest confidence interactions, for which we perform a small-scale knockdown screen that leads to the identification of three HIV-1 protein binding RNA interactors involved in HIV-1 replication (AFF2, H4C9 and RPLP0).
Authors
- Wim Trypsteen (ORCID: https://orcid.org/0000-0001-9066-4932)
- Kimberly Verniers (ORCID: https://orcid.org/0000-0002-7693-5908)
- Nevan J. Krogan (ORCID: https://orcid.org/0000-0003-4902-337X)
- Tinus Schynkel (ORCID: https://orcid.org/0000-0001-5936-0906)
- Gwendolyn Μ. Jang (ORCID: https://orcid.org/0000-0001-7806-9874)
- Pieter Mestdagh (ORCID: https://orcid.org/0000-0001-7821-9684)
- Willem van Snippenberg (ORCID: https://orcid.org/0000-0001-8903-3631)
- Linos Vandekerckhove (ORCID: https://orcid.org/0000-0002-8600-1631)
Institutions
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- Ghent University Hospital (BE)
- Quantitative BioSciences (US)
- VIB-UGent Center for Medical Biotechnology (BE)
Publication Details
- Journal
- EMBO Reports
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1038/s44319-024-00222-6
- Citations
- 3
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- ViiV Healthcare
- Fonds Wetenschappelijk Onderzoek
- Universiteit Gent
- Vlaamse regering